Medical Advisory Boards: Refreshing Companies Clinical, Marketing and Market Access Strategies, One Meeting at a Time

Sarah Ray, regulatory affairs and safety researcher
By Sarah Ray,
Senior Research Analyst

Medical advisory boards take a number of forms across life science companies clinical, marketing and market access teams.  Although recent legislature limits how companies interact with the physicians and other key opinion leaders (KOLs) who most commonly staff these boards, they do not decrease the importance of these institutions. When leveraged appropriately, medical advisory boards — which combine members’ expertise and unique insights — are a huge asset to the industry as a whole. Continue reading


Are You Ready to Optimize Your Medical Publications Department?

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Within the life sciences industry, medical publications groups are tasked with a critical responsibility: sharing company findings and new scientific brand support details with the healthcare community.  To ensure that these key medical communications groups are working efficiently, companies should provide them with the resources needed to meet demands.  Whether teams are responsible for 5 or 500 publications per year, companies should right-size the staffing and budgets allocated to these efforts.  They should also consider company structure. Cutting Edge Information’s recent study on medical publications departments highlights how top-performing pharmaceutical and device organizations resource and measure performance across various high- and low-output team structures. Continue reading



Pharma Key Opinion Leader Development Requires a Personal Touch

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

At a recent conference I attended focused on pharma advisory boards, one of the presentations focused on KOL relationships and best practices for maintaining effective contact with thought leaders.  One of the key takeaways for me in terms of pharma key opinion leader development was the need to ensure that there is a personal touch to communications.  This corroborated a lot of what we’ve seen here in our research at Cutting Edge Information.  Continue reading


Surveyed Companies Reveal Pharmaceutical Ad Board Costs

David Richardson, pharmaceutical commercialization and launch expert
By David Richardson,
Director of Research

Ad boards – and the related issue of ad board costs – are growing areas of interest in the life sciences industry. A sampling of companies surveyed by Cutting Edge Information recently reported their spending for an average pharmaceutical ad board conducted in the US. Among surveyed companies, the average multinational clinical ad board convened in the US costs $129,000. A US national clinical ad board costs these same companies an average of $78,000 while a local ad board costs an average of $36,000. Continue reading


Basing Fair-Market Value on Physician Salary Data Isn’t Enough Anymore

Elio Evangelista, physician fair-market value expert
By Elio Evangelista,
Senior Director

Medical Marketing and Media published an article recently stating that 46% of the highest-paid physicians (orthopedists at $413,000 annually) are unsatisfied with their pay. This is a telling metric given the discussions that compliance executives throughout the pharmaceutical industry are having around determining fair-market value (FMV) for the physicians their companies work with.  Continue reading


The Demand for and Implementation of Medical Publications Transparency

I play video games often in my free time and hold a particular love for the Portal series.  At the end of the first game, there is a cute song that contains the line, “We do what we must because we can.”  There aren’t many similarities I can find between pharma and the fictional Aperture Science company from the games (pending any news regarding armies of mantis men).  But that particular line lies parallel to the situation in which many companies find themselves as the digital age continues to bloom.  Medical publications transparency, in particular, is one area in which several companies are only beginning to actually do what they must. Continue reading


Making the Most of Scientific Advisory Boards with Clear Objectives

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

When bringing together a group of active clinicians and specialists for scientific advisory boards, companies should make sure to maximize the effectiveness of the resources seated around the table.  Each person in the room has a different set of experiences, all of which are invaluable to the clinical trial being discussed. The process of converting this aggregated knowledge into a better product is what differentiates an average advisory board from a truly successful one. Continue reading


Looking Outside the Box: How Medical Communications Groups Engage the Medical Community

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

As the life sciences industry grows, companies internal groups must also evolve to match changing demands.  One surveyed pharmaceutical executive explained, “By and large, companies seem to know that consumers want more face time with organizations at a gut level, and companies are moving along that path.”  In response to this movement, medical communications teams are experiencing increasing visibility within both medical affairs and life science companies at large. Continue reading